![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Akers Bio | LSE:AKR | London | Ordinary Share | COM SHS NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 57.50 | 50.00 | 65.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/10/2014 16:31 | Slight 'bargain' compared to nasdaq price / exchange. | ![]() mcmather | |
16/10/2014 11:29 | Not sure; made a fair amount of money here after it dipped to the all time low of 0.7p. That PIFA PF4 / Pluss device works (quicker and cheaper than alternatives). With 26m receiving heparin each year in the US and EU you only need a small part of that market (reference to $100 per device though think that is for the Pluss device). Then with approval in China & India before year end who knows. Plus all the other products and the recent partnership with Konica Minolta. The main problem that I see is whether those in charge here are capable or just massive clowns? And fully appreciate concerns here re AIM, etc. Although the company is also on nasdaq and those involved here will no doubt be being carefully watched as a result. | ![]() mcmather | |
16/10/2014 08:04 | keeping hoping dude, cos hope is all it is... | ![]() deanroberthunt | |
15/10/2014 16:08 | Whilst the presentation saw a massive positive reaction from US Investors.....includ | ![]() mcmather | |
15/10/2014 16:07 | PIFA Heparin PF4 / Pluss "significant uptake in Q3 2014 and which has continued and more so in Q4 2014" with Typenex having come on board; “it took them till Sept 2014” to effectively get themselves sorted. Cardinal & Fisher – two of the other main distributors – have also seen increased sales as well..... Presumably this will be borne out by the soon to be published Q3 2014 results. | ![]() mcmather | |
15/10/2014 16:01 | Breath Ketone now available in EU. Breath Ketone launches in the US 2015. Breath Asthma launches in the US 2015. PIFA Chlamydia launches in the US 2015. | ![]() mcmather | |
15/10/2014 15:59 | Sell Breath Ketone device for $2; margin will be $1.35. PIFA Heparin PF4 / Pluss; 13m will receive heparin in the US with a similar amount in the EU. The device will have approval in China AND India by year end (2014). Already establishing distribution agreements in the EU. Tri-Cholesterol device will sell for $10; 80% margin. However, there is a profit motive here for the physician (US). In the process of finalising US distribution agreements for Tri-C in the US. Recent contract for $864K for Tri-C in Aus. “Expect similar in Middle East”. PIFA Pluss Troponin I; heart attack device partnered with Konica Minolta. | ![]() mcmather | |
15/10/2014 15:27 | Redchip Global Online CEO Conference to begin in 5 mins; of course redchip being a paid mate of the good doctor.... | ![]() mcmather | |
10/10/2014 12:22 | drip drip drip, like a leaking pipe AIM is hell | ![]() deanroberthunt | |
10/10/2014 11:02 | Common misconception.Classi I hope not to ever find out but unfortunately may head that way eventually. Good luck to our current share price. | ![]() algernon2 | |
09/10/2014 22:38 | Dunno - that's a bit like saying at least it will be warm in hell. | ![]() mcmather | |
09/10/2014 09:56 | At least their profile is being raised - even if they have to pay Red Chip to say nice, positive things. Unlike the limbo they were in not so long ago | werewolfie | |
09/10/2014 09:17 | Nothing new except for likely upsetting most of Australia; no harm in that unless, of course, you are hoping to do business with them..... | ![]() mcmather | |
07/10/2014 12:14 | Agree Dean - which is why my AIM investments are limited to Akers | werewolfie | |
07/10/2014 11:58 | don't get your hopes up, AIM has a propensity to disappoint. | ![]() deanroberthunt | |
07/10/2014 10:58 | I hope to see reduced costs as well. At least the fees have been paid for the Nasdaq float | werewolfie | |
07/10/2014 08:39 | Will the Q3 results be around the same time or too soon? AKER to present at @RedChipNation Global Online #CEO Conference on Oct 15 at 10.30am ET Time to see whether Eddie Kendrick is earning his money. Also need to see a significant trimming of the costs for the quarter. | ![]() mcmather | |
01/10/2014 00:09 | Dangerous Dave touting for business again 30 Sept 2014: | ![]() mcmather | |
26/9/2014 10:17 | 3rd quarter completed next week. This coincides with Eddie Hendrick's first six months with akers. Early doors into his tenure the good doctor was proclaiming how eddie was already working wonders. He has also had the PIFA Heparin Pluss to sell whereas this was not previously available to TAN. In simple terms, is Hendrick earning his way?? | ![]() mcmather | |
19/9/2014 11:16 | Your Dad can stay put now WereWolfie. Good Morning to everyone on here on this auspicious United(still) day. | ![]() algernon2 | |
18/9/2014 14:32 | Nicolas Daurel @AkersBio's VP International Sales for EMEA presented at the #PatientSafety conference in #Dubai today hxxp://www.patientsa .@AkersBio is bringing the #BreathKetone test to the region as a vital tool to help #diabetics manage the disease Daurel told the conference. | ![]() mcmather | |
18/9/2014 08:37 | Politcians never do; Salmond should be shot; like an Arab revolutionery; The time to have done this was before North Sea Oil was spent | ![]() norbus | |
17/9/2014 17:57 | Im from Scotland - i wont be losing any sleep on Thu night trust me. A lot of the Yes vote is coming from people who are undeniably passionate about Scotland (and Braveheart) but arent thinking that far into the future. | werewolfie |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions